Hematology: curing CML with imatinib--a dream come true? (Q47594277)

4 February 2018

title

Hematology: curing CML with imatinib--a dream come true? (English)

1 reference

4 February 2018

author name string

Michael Deininger

series ordinal

1

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 February 2011

1 reference

4 February 2018

Nature Reviews Clinical Oncology

published in

1 reference

4 February 2018

volume

8

1 reference

4 February 2018

issue

3

1 reference

4 February 2018

page(s)

127-128

1 reference

4 February 2018

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.17

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.17

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.17

Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.17

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.17

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.17

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.17

Minimum viable population size: A meta-analysis of 30 years of published estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.17

The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21283128

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2011.17

1 reference

4 February 2018

1 reference

4 February 2018